Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Pulmonary surfactant nanoparticles for lung‐targeted and dose‐efficient delivery

  • Fernández Méndez, Laura
  • Piñol Cancer, Marina
  • Souto Riobó, Itziar
  • Urkola Arsuaga, Ainhize
  • González Lozano, Elena
  • Fernández Folgueral, Irene
  • de Alejo, Claudia Miranda Pérez
  • Azkargorta, Mikel
  • Elortza, Felix
  • Tagliaferro Quiñonero, Alberto
  • Silvio, Desire Di
  • Cañadas Benito, Olga
  • Maiz, Jon
  • Pérez Gil, Jesús
  • Ramos Cabrer, Pedro
  • Ruíz Cabello, Jesús
  • Carregal Romero, Susana
Although pulmonary drug delivery enables lung-targeted therapy, its clinical efficacy is often limited by inflammation, heterogeneous deposition, and physiological barriers such as mucociliary clearance and phagocytic uptake. Here, we report a biomimetic platform based on pulmonary surfactant nanoparticles (PSNPs) that preserves native surfactant proteins and biophysical functionality, resulting in enhanced pulmonary delivery. Microfluidic synthesis yielded highly uniform PSNPs with improved encapsulation efficiency and colloidal stability, while markedly increasing surfactant protein retention from 33% using conventional extrusion to 95% via microfluidics, corresponding to a 2.4-fold improvement. Functionally, PSNPs exhibited superior interfacial activity compared to lipid-only liposomes, increasing surface pressure from 5–10 mN/m to 25–30 mN/m, and achieved an approximately 80-fold enhancement in alveolar cellular uptake. In vitro, nintedanib-loaded PSNPs significantly reduced fibroblast migration, proliferation, collagen deposition, and TGF-β secretion relative to free drug and control formulations. In vivo, PSNPs demonstrated high pulmonary retention (95% injected dose per gram of lung tissue), efficient penetration into fibrotic regions, and minimal off-target accumulation in the liver (0.5%). Therapeutic efficacy was confirmed in a bleomycin-induced pulmonary fibrosis model, where PSNPs improved lung function and restored tissue architecture at doses as low as 0.5 mg/kg. Collectively, these results establish PSNPs as a robust lung-targeted nanotherapeutic platform, where microfluidic synthesis enables enhanced biomimicry, improved protein preservation, and superior therapeutic performance compared to conventional fabrication methods.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NIR-II Photoresponsive magnetoliposomes for remote-controlled release and magnetic resonance imaging

  • Fernández-Méndez, Laura
  • Fernández-Afonso, Yilian
  • Martínez-Vicente, Pablo
  • Urkola-Arsuaga, Ainhize
  • Miranda-Pérez de Alejo, Claudia
  • Pisa, Irati L. de la
  • Plaza-García, Sandra
  • Ruíz-Cabello, Jesús
  • Ramos-Cabrer, Pedro
  • Gutiérrez, Lucía
  • Carregal-Romero, Susana
Magnetic nanoparticles, especially iron oxide nanoparticles, have become versatile and widely used tools in nanomedicine due to their unique magnetic properties, biocompatibility, and tunable functionality. Liposomes have further enhanced the potential of iron oxide nanoparticles by serving as effective nanocarriers with advantages such as drug coencapsulation and enhanced molecular imaging properties. In this study, we present magnetoliposomes composed of ultrasmall free-floating iron oxide nanoparticles inside liposomes (LP-IONPs) and thermoresponsive phospholipids, which were designed as dual T2-T1 magnetic resonance imaging (MRI) contrast agents for image-guided liposome degradation and infrared light-responsive nanocarriers in the second biological window for remote-controlled drug delivery. We demonstrated a dynamic shift from T2 to T1 MRI contrast during intracellular degradation of LP-IONPs, along with successful light-activated drug release in cancer cells. Biodistribution studies using MRI and histological analysis confirmed their potential for in vivo applications. These results highlight the potential of LP-IONPs as image-guided and remote-controlled drug delivery systems., S.C.R. thanks the MCIN/AEI 10.13039/501100011033 projects (PID2019-106139RA-100, CNS2023-143944, RYC2020-030241-I, and PID2022-142842OB-I00), the Ikerbasque (Basque Foundation for Science), and the Ramón Areces Foundation (CIVP21S13151). J.R.C. is funded by MCIN/AEI/10.13039/501100011033 (PID2021-123238OB-I00), the Basque Government through the Elkartek 2024 program (bmG24), and R&D projects in Health (grant number 2022333041). S.C.R. and J.R.C. thank IKERBASQUE for its support. L.G. thanks Project CNS2023-144321, funded by MICIU/AEI/10.13039/501100011033 and NextGenerationEU/PRT, and Fondo Social del Gobierno de Aragón (grupo DGA E15-23R). We also thank the Fundación contra la Hipertensión Pulmonar for funding (Empathy). CIBERES and CIBERBBN were co-funded by FEDER and ISCIII., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

NIR-II Photoresponsive Magnetoliposomes for Remote-Controlled Release and Magnetic Resonance Imaging

  • Fernández-Méndez, Laura
  • Fernández-Afonso, Yilian
  • Martínez-Vicente, Pablo
  • Urkola-Arsuaga, Ainhize
  • Miranda-Pérez de Alejo, Claudia
  • L. de la Pisa, Irati
  • Plaza-García, Sandra
  • Ruíz-Cabello, Jesús
  • Ramos-Cabrer, Pedro
  • Gutiérrez, Lucía
  • Carregal-Romero, Susana
Magnetic nanoparticles, especially iron oxide nano-particles, have become versatile and widely used tools in nanomedicinedue to their unique magnetic properties, biocompatibility, and tunablefunctionality. Liposomes have further enhanced the potential of ironoxide nanoparticles by serving as effective nanocarriers with advantagessuch as drug coencapsulation and enhanced molecular imagingproperties. In this study, we present magnetoliposomes composed ofultrasmall free-floating iron oxide nanoparticles inside liposomes (LP-IONPs) and thermoresponsive phospholipids, which were designed asdual T2-T1 magnetic resonance imaging (MRI) contrast agents forimage-guided liposome degradation and infrared light-responsivenanocarriers in the second biological window for remote-controlleddrug delivery. We demonstrated a dynamic shift from T2 to T1 MRIcontrast during intracellular degradation of LP-IONPs, along with successful light-activated drug release in cancer cells.Biodistribution studies using MRI and histological analysis confirmed their potential for in vivo applications. These results highlightthe potential of LP-IONPs as image-guided and remote-controlled drug delivery systems.